Health TrialsbyHealthPanel

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

ConditionsDiabetic RetinopathyRetinal Vein Occlusion
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCHU de Reims

About this trial

CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test.

The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

over 18 years old

with social security affiliation

any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids, or immunosuppressive agents

any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation

Disqualifiers

Patients with C-reactive protein CRP > 10mg/mL (serum sampling during surgery)

Trial design

Design model

Single group

Treatments tested in this trial

  • sampling of ophthalmic liquid

    Other intervention

    aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery

Treatment groups

120 Participants
are divided into 1 treatment group
Group A: Patients with ophthalmic surgeryExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

sCD160 concentration in the vitreous humor

ELISA test

Time frame
Day 0
2

sCD160 concentration in the aqueous humor

ELISA test

Time frame
Day 0

Secondary outcomes

1

sCD160 concentration in the serum

ELISA test

Time frame
Day 0
2

Diabetic retinopathy severity

Angiography

Time frame
Day 0
3

Vascular endothelial growth factor (VEGF)

LUMINEX test

Time frame
Day 0
4

Placenta Growth Factor-1(PlGF)

LUMINEX test

Time frame
Day 0

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

CHU de Reims

Lead sponsor

Source ClinicalTrials.gov
Apply now